NCT02221921Unknown不适用
Clinical Evaluation of the Safety and Performance of the MicroPort's Transcatheter Aortic Valve and Delivery System for Treatment of Severe Aortic Stenosis
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 89
- 试验地点
- 1
- 主要终点
- All cause mortality or major stroke at 12 months.
研究概览
简要总结
The objective of this study is to evaluate the safety and effectiveness of the MicroPort's Valve and delivery system for transcatheter aortic valve implantation (TAVI) in severe aortic stenosis who are considered unsuitable for Surgical Valve Replacement.
详细描述
- Evaluate the performance, safety and clinical benefit of MicroPort's aortic valve prosthesis and delivery system in intervention by peripheral artery.
- The study Continuous observe 12 months of safety and efficacy. Approximately 89 patients are recruited in the study with native aortic valve stenosis which are considered unsuitable for Surgical Valve Replacement.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or older, male or non pregnant women;
- •Senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient ≥ 40 mmHg, or jet velocity ≥ 4.0 m/s, or an aortic valve area (AVA) of < 1.0 cm2 (or AVA index < 0.6 cm2/m2)
- •Symptomatic due to aortic valve stenosis as demonstrated by NYHA (New York Heart Association) Functional Class ≥ II
- •Expectation of life>12 months
- •Calcific aortic stenosis, which is suitable for transcatheter aortic valve implantation anatomically
- •is evaluated by at least two cardiovascular physicians, and they agreed that medical factors precluding operation suitable for surgery (the probability of death or serious, irreversible morbidity exceeded 50%)
- •The subject agreed to comply follow-up evaluation
排除标准
- •Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment
- •aortic valve is a congenital unicuspid valve, or is non-calcified.
- •Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days
- •Implanted any heart valve prosthesis, prosthetic valve ring, severe（>3＋）mitral valve insufficiency
- •Blood dyscrasia such as leukopenia (WBC < 3×109/L), acute anemia (Hgb < 90 g/L), thrombocytopenia (PLT < 50×109/L), bleeding diathesis, or history of coagulopathy.
- •Untreated clinically significant coronary artery disease requiring revascularization
- •Hemodynamic instability requiring mechanical cardiac assist or mechanical hemodynamic support devices
- •Need for emergency surgery for any reason
- •Hypertrophic cardiomyopathy with or without obstruction
- •Severe ventricular dysfunction with LVEF (Left ventricular ejection fraction) < 20%
- •Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- •Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months
- •A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, Nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated.
- •Native aortic annulus size < 17 mm or> 29 mm.
- •Patient refuses aortic valve replacement surgery.
- •Cerebrovascular Accident (CVA) within 6 months, including TIA (transient ischemic attack).
- •Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis.
- •Life expectancy < 12 months
- •Significant abdominal or thoracic aorta disease, including aneurysm, marked tortuosity (hyperacute bend), aortic arch atheroma, narrowing of the abdominal aorta (especially with calcification and surface irregularities), or severe "unfolding" and tortuosity of the thoracic aorta
- •Iliofemoral vessel characteristics that would preclude safe placement of 16F to 19F introducer sheath such as severe obstructive calcification, severe tortuosity
- •Active bacterial endocarditis or other active infections.
- •Bulky calcified aortic valve leaflets in close proximity to coronary ostia
- •severe incapacitating dementia.
- •Currently participating in an investigational drug or another device study that has not reached its primary endpoint.
- •Researchers identify that the patients with poor compliance who cannot be completed in accordance.
结局指标
主要结局
All cause mortality or major stroke at 12 months.
时间窗: 12 months
次要结局
- The improvement of heart function(30 days, 3, 6 and 12 months)
- MACCE(major adverse cardiovascular and cerebrovascular events)(30 days, 3, 6 and 12 months)
- Device success(7 days post-operation)
- Valve performance(30 days, 3, 6 and 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Safety and Performance Study of the Moderato SystemHypertension Resistant to Conventional TherapyBradycardiaAtrioventricular BlockNCT02282033BackBeat Medical Inc57
进行中（未招募）
不适用
Bronchoscopic Microwave Ablation of Lung TissueLung CancerNCT05786625Creo Medical Limited35
已完成
1 期
Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic AneurysmsAbdominal Aortic AneurysmsNCT01328197Bolton Medical30
招募中
不适用
Assessing the Usability and Reliability of the Prototype Prosthesis DevicesAmputationTraumatic AmputationsLeg AmputationNCT06616402Fondazione Don Carlo Gnocchi Onlus15
招募中
不适用
VitaFlow™ Transcatheter Aortic Valve System Post-market Study-The LAUNCH StudyAortic Valve StenosisNCT04414865Shanghai MicroPort CardioFlow Medtech Co., Ltd.100